Floatz logo

Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine

Ovarian Mixed Cell Adenocarcinoma

Mayo ClinicvaccinePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the Ovarian Mixed Cell Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 3BBB
Inno-206
National Cancer Institute (NCI)
Phase 3BB
Carboplatin
National Cancer Institute (NCI)
Phase 3BB
Cediranib
National Cancer Institute (NCI)
Phase 3BB
Olaparib
National Cancer Institute (NCI)
Phase 3BB

View all 41 →

Same molecule, other indications

Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine is also rated in:

ovarian endometrioid adenocarcinomaDormant
BB
Indicative ·
65 / 100
View asset →
fallopian tube serous adenocarcinomaDormant
BB
Indicative ·
65 / 100
View asset →
primary peritoneal serous adenocarcinomaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →